Asset
Lifileucel
Iovance Biotherapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06481592 | phase2 | recruiting | 2024-10-29 | 2028-05-01 | Iovance Biotherapeutics, Inc. | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. |
| NCT07288203 | phase2 | active_not_recruiting | 2025-11-28 | 2032-12-01 | Iovance Biotherapeutics, Inc. | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma |
| NCT07741877 | phase2 | not_yet_recruiting | 2026-09-01 | 2033-09-01 | Iovance Biotherapeutics, Inc. | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma |
| NCT04614103 | phase2 | recruiting | 2021-05-07 | 2030-12-01 | Iovance Biotherapeutics, Inc. | Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer |
| NCT03419559 | phase2 | withdrawn | 2018-02-28 | 2021-12-01 | Iovance Biotherapeutics, Inc. | Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 125773 | BLA | Iovance Biotherapeutics, Inc. |
Marketed products (1)
- AMTAGVI